Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage

Down in metal with arrow

Jonathan Kitchen

Myriad Genetics (NASDAQ:MYGN) is down ~20% in Friday trading following reports that UnitedHealth Group (UNH) will no longer cover the company’s genetic test that helps to determine which mental health medications are likely to work with an individual patient.

Notes

Leave a Reply

Your email address will not be published. Required fields are marked *